Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 231 to 240 of 1003 total matches.

Once-a-week Alendronate (Fosamax)

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):26 |  Show IntroductionHide Introduction

In Brief: Exenatide (Byetta) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Patients may be asking about reports in the lay press that exenatide (Byetta - Med Lett Drugs Ther 2005; 47:45), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been used by diabetics and non-diabetics to lose weight. Approved by the FDA to improve glycemic control in patients with type 2 diabetes not controlled by metformin, a sulfonylurea or both, it is given by subcutaneous injection before the morning and evening meals. In clinical trials, some diabetic patients treated with the drug lost weight. No data are available on use in non-diabetics....
Med Lett Drugs Ther. 2006 Mar 13;48(1230):21 |  Show IntroductionHide Introduction

In Brief: Sodium Phosphate Colonoscopy Preps

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Last year, a Medical Letter article reviewing colonoscopy preparations warned that oral sodium phosphate preparations, such as Fleet Phospho-Soda solution and Visicol tablets, could cause significant electrolyte disturbances and, rarely, renal failure (Med Lett Drugs Ther 2005; 47:53). A subsequent report documented acute phosphate nephropathy and renal failure in 21 patients who had used sodium phosphate before colonoscopy (GS Markowitz et al. J Am Soc Nephrol 2005; 16:3389). Seventeen of these patients were women and 14 were taking an angiotensin-converting enzyme (ACE) inhibitor or...
Med Lett Drugs Ther. 2006 May 22;48(1235):41 |  Show IntroductionHide Introduction

In Brief: Plan B OTC

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Med Lett Drugs Ther. 2006 Sep 11;48(1243):75 |  Show IntroductionHide Introduction

Correction: Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007  (Issue 1276)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
On page 100 of the article "Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):104 |  Show IntroductionHide Introduction

In Brief: Influenza Developments

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008  (Issue 1282)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir...
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-4 |  Show IntroductionHide Introduction

In Brief: Meningococcal Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Apr 07, 2008  (Issue 1283)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines (Med Lett Drugs Ther 2005; 47:29) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin (Cipro, and others) 500 mg has been used for prophylaxis after close...
Med Lett Drugs Ther. 2008 Apr 7;50(1283):25 |  Show IntroductionHide Introduction

Correction: Bendamustine (Treanda) for CLL and NHL

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
Med Lett Drugs Ther. 2008 Dec 1;50(1300):96 |  Show IntroductionHide Introduction

Correction: A Sumatriptan Needle-Free Injection for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010  (Issue 1342)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Jordan W. Smoller, M.D., Sc.D ...
In The Medical Letter article on Sumatriptan Needle-Free Injection for Migraine (2010; 52:50), on page 51, in Table 2, the injection volumes of Imitrex and Sumaval are listed as 5 mL. They should be 0.5 mL.
Med Lett Drugs Ther. 2010 Jul 12;52(1342):56 |  Show IntroductionHide Introduction

A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010  (Issue 1351)
of Neurology. Neurology 2008; 70:1699. 3. R Benecke et al. A new botulinum toxin type A free of complexing ...
The FDA has approved incobotulinumtoxinA (Xeomin – Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
Med Lett Drugs Ther. 2010 Nov 15;52(1351):90-1 |  Show IntroductionHide Introduction